✦ LIBER ✦

Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244

✍ Scribed by Christiane Querfeld; Keith Duffy; George Magel; Darryl Oble; Ezra E.W. Cohen; Christopher R. Shea

Book ID: 116585763
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 791 KB
Volume: 64
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2009.06.070

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

26 ORAL Phase Ib and pharmacodynamic stu

26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies

✍ A. Adjei; R.B. Cohen; W.A. Franklin; J. Molina; S. Hariharan; E. Temmer; S. Brow 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 82 KB

A phase 1 trial of the MEK1/2 inhibitor

A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC)

✍ Koh, P. Keng; Califano, R.; Dean, E.; Kosmin, J.; Ataman, O.; Jackson, A.; Black 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 97 KB

265 POSTER A MEK1/2 inhibitor, AZD6244 (

265 POSTER A MEK1/2 inhibitor, AZD6244 (ARRY-142886), shows beneficial effects when combined with standards of care or novel therapies – mechanistic characterisation suggests a role for apoptosis

✍ S.V. Holt; A. Logie; B.R. Davies; M. Cockerhill; N. Haupt; N.J. Curtis; D.M. Hic 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Intrinsic resistance to the MEK1/2 inhib

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

✍ Kathryn Balmanno; Simon D. Chell; Annette S. Gillings; Shaista Hayat; Simon J. C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 466 KB

## Abstract Mutations in __KRAS__ or __BRAF__ frequently manifest in constitutive activation of the MEK1/2‐ERK1/2 signalling pathway. The MEK1/2‐selective inhibitor, AZD6244 (ARRY‐142886), blocks ERK1/2 activation and is currently undergoing clinical evaluation. Tumour cells can vary markedly in th

A phase I, open-label, randomized crosso

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

✍ Suzanne Leijen; Patricia M. M. B. Soetekouw; T. R. Jeffry Evans; Marianne Nicols 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 303 KB